company background image
ATHA logo

Athira Pharma NasdaqGS:ATHA Stock Report

Last Price

US$0.64

Market Cap

US$24.6m

7D

-3.1%

1Y

-67.8%

Updated

08 Dec, 2024

Data

Company Financials +

Athira Pharma, Inc.

NasdaqGS:ATHA Stock Report

Market Cap: US$24.6m

ATHA Stock Overview

A late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. More details

ATHA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Athira Pharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Athira Pharma
Historical stock prices
Current Share PriceUS$0.64
52 Week HighUS$4.30
52 Week LowUS$0.41
Beta3
11 Month Change-3.76%
3 Month Change28.41%
1 Year Change-67.76%
33 Year Change-95.31%
5 Year Changen/a
Change since IPO-96.29%

Recent News & Updates

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

Shareholder Returns

ATHAUS PharmaceuticalsUS Market
7D-3.1%0.8%1.0%
1Y-67.8%13.4%32.3%

Return vs Industry: ATHA underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: ATHA underperformed the US Market which returned 32.3% over the past year.

Price Volatility

Is ATHA's price volatile compared to industry and market?
ATHA volatility
ATHA Average Weekly Movement17.6%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: ATHA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ATHA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201166Mark Littonwww.athira.com

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and Dementia with Lewy bodies. The company’s product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis.

Athira Pharma, Inc. Fundamentals Summary

How do Athira Pharma's earnings and revenue compare to its market cap?
ATHA fundamental statistics
Market capUS$24.56m
Earnings (TTM)-US$109.22m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATHA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$109.22m
Earnings-US$109.22m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.82
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ATHA perform over the long term?

See historical performance and comparison